RESUMO
In a double-blind study, 15 cigarette smokers self-monitored 10 withdrawal symptoms. For the first 21 days (baseline), subjects received doxepin hydrochloride, up to 150 mg/day, or inert medication while continuing to smoke. On day 22, they were instructed to stop smoking; medication was continued. Withdrawal symptoms on the first 28 days of treatment (baseline and 7 days of attempted cessation) were analyzed. During cessation, subjects taking doxepin reported significantly less craving for cigarettes. Results from this study and others suggest that antidepressants may attenuate the severity of symptoms during withdrawal from addictive substances.
Assuntos
Doxepina/uso terapêutico , Prevenção do Hábito de Fumar , Síndrome de Abstinência a Substâncias/tratamento farmacológico , Adulto , Ritmo Circadiano , Ensaios Clínicos como Assunto , Coleta de Dados , Método Duplo-Cego , Doxepina/administração & dosagem , Esquema de Medicação , Humanos , Placebos , Síndrome de Abstinência a Substâncias/psicologiaRESUMO
Two patients taking stable doses of standard tricyclic antidepressants were additionally treated with fluoxetine as the first step in a transition to that drug. After fluoxetine was added, both patients' plasma tricyclic antidepressant levels increased substantially. Adverse side effects occurred in one patient. Fluoxetine may increase the plasma levels of standard tricyclic antidepressants and the likelihood of tricyclic antidepressant toxicity.
Assuntos
Antidepressivos Tricíclicos/sangue , Transtorno Depressivo/tratamento farmacológico , Fluoxetina/farmacologia , Idoso , Transtorno Depressivo/sangue , Quimioterapia Combinada , Feminino , Fluoxetina/efeitos adversos , HumanosRESUMO
In a double-blind study, 19 adults received bedtime doses of either 150 mg of doxepin hydrochloride (N = 9) or placebo (N = 10). After 3 weeks the subjects were instructed to stop smoking and continue taking medication for 4 additional weeks. Cessation was reported by all nine doxepin subjects 1 week after cessation and by seven doxepin subjects 9 weeks after cessation. One placebo subject reported cessation. Cotinine assays generally confirmed cessation but were subject to interpretation. Doxepin assays suggested that the precessation level was associated with cessation. Further studies with larger samples and extended follow-up are needed to determine the reliability of these results.